Loading stock data…
MDGL
$539.50+20.64 (+3.97%)
Market OpenUpdated 10:57 AM EDT
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Madrigal Pharmaceuticals, Inc. in the Healthcare sector is trading at $518.87. Wall Street consensus targets $674.36 (14 analysts), implying a +30.0% move over the next 12 months. The stock is currently 16% below its 52-week high of $615.00, remaining 8.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +30.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$539.50
Potential Downside
0%
Whystock Fair Value$539.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$674.36+25.0%
Range$550.00 – $964.00
Fundamentals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-46.77%
Volume
Today's trading volume
60,536
Recent News
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth
Madrigal Pharmaceuticals (MDGL) is back in focus after its first quarter 2026 earnings, where Rezdiffra delivered 127% year over year net sales growth to US$311.3 million, while the company still reported a US$94.4 million net loss. See our latest analysis for Madrigal Pharmaceuticals. The stock has been volatile, with a 1-day share price decline of 0.90%, a 90-day share price return of 11.99%, and a 1-year total shareholder return of 78.54% as Rezdiffra sales and pipeline updates remain in...
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Madrigal Pharmaceuticals Q1 Earnings Call Highlights
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company’s earnings call, management highlighted patient growth,
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Madrigal Pharmaceuticals, Inc.'s Q1 2026 earnings call
Madrigal (MDGL) Q1 2026 Earnings Transcript
Rezdiffra has achieved blockbuster status generating more than $1.1 billion in net sales in the last 12 months. When you put those fundamentals together, the future growth opportunity is quite remarkable. Beyond F2/F3 MASH, we're advancing our F4C outcomes trial, where an indication expansion could double the opportunity for Rezdiffra.